Actively Recruiting
Phase 3 Study Comparing Oral Daraxonrasib to Standard Observation in Patients With Resected Pancreatic Ductal Adenocarcinoma After Chemotherapy
Led by Revolution Medicines, Inc. · Updated on 2026-10-23
500
Participants Needed
86
Research Sites
60 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a new drug called daraxonrasib compared to standard observation care in patients with pancreatic ductal adenocarcinoma PDAC who have had surgery to remove their cancer. This Phase 3, global, randomized, and open-label study focuses on whether daraxonrasib can improve the length of time patients remain free from disease after completing chemotherapy before or after surgery. Participants will be randomly assigned to one of two groups one receiving oral daraxonrasib tablets and the other receiving standard of care observation without additional treatment. The study will monitor patients for up to approximately five years to assess outcomes such as disease-free survival and overall survival. During the study, participants will undergo regular evaluations including health assessments and laboratory tests to track disease status, safety, and drug effects. Researchers will measure disease-free survival as the primary outcome, along with secondary outcomes like overall survival and drug safety over several years. Participants are expected to attend scheduled visits and follow study procedures throughout the trial duration.
CONDITIONS
Brief Title
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Research Team
R
Revolution Medicines Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here